Inflammatory effects of blood leukocytes: Association with vascular function in neuropeptide y proline 7-genotyped type 2 diabetes patients

Diabetes and Vascular Disease Research

Volumn 8, Issue 3, 2011, Pages 221-228

  Kakko, Tanja ^a   Jaakkola, Ulriikka ^a   Raitakari, Olli T ^b   Kallio, Jaana ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Leu7Pro polymorphism; Leukocyte activation; NPY; Type 2 diabetes; Vascular function

Indexed keywords

GAMMA INTERFERON; LEUCINE; NEUROPEPTIDE Y; PROLINE; THROMBOPLASTIN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR PARAMETERS; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENOTYPE; GRANULOCYTE; HETEROZYGOTE; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; WILD TYPE;

AGED; ANALYSIS OF VARIANCE; BRACHIAL ARTERY; CAROTID ARTERY DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FINLAND; FLOW CYTOMETRY; GENOTYPE; HUMANS; INFLAMMATION; INTERFERON-GAMMA; LEUKOCYTES; LINEAR MODELS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; PHENOTYPE; PROLINE; RISK ASSESSMENT; RISK FACTORS; VASODILATION;

EID: 80052069767     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111415882     Document Type: Article

References (41)

1. Boyle PJ. Diabetes mellitus and macrovascular disease: Mechanisms and mediators. Am J Med 2007; 120(9 Suppl 2): S12-S17. (Pubitemid 47361038)
2. Rask-Madsen C and King GL. Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 46-56. (Pubitemid 46006612)
3. Osterud B and Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 2003; 83: 1069-1112. (Pubitemid 37222268)
4. Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W, Encinas J, et al. Th1/Th2 cells in inflammatory disease states: Therapeutic implications. Expert Opin Biol Ther 2004; 4: 1887-1896. (Pubitemid 39627140)
5. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43. (Pubitemid 29292698)
6. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, et al. Cross-regulatory roles of interleukin (IL)?12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-2138. (Pubitemid 26143968)
7. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009; 7(Suppl 1): 328-331.
8. van Oostrom AJ, van Wijk JP, Sijmonsma TP, Rabelink TJ and Castro Cabezas M. Increased expression of activation markers on monocytes and neutrophils in type 2 diabetes. Neth J Med 2004; 62: 320-325. (Pubitemid 39406483)
9. Kansas GS. Selectins and their ligands: Current concepts and controversies. Blood 1996; 88: 3259-3287. (Pubitemid 26365560)
10. Weber C. Novel mechanistic concepts for the control of leukocyte transmigration: Specialization of integrins, chemokines, and junctional molecules. J Mol Med 2003; 81: 4-19. (Pubitemid 36207879)
11. Springer T, Galfre G, Secher DS and Milstein C. Mac-1: A macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol 1979; 9: 301-306. (Pubitemid 9205194)
12. Marutsuka K, Hatakeyama K, Yamashita A and Asada Y. Role of thrombogenic factors in the development of atherosclerosis. J Atheroscler Thromb 2005; 12: 1-8.
13. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez JJ, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006; 98: 70-74. (Pubitemid 43902682)
14. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001; 159: 145-151. (Pubitemid 33016631)
15. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4: 1434-1437. (Pubitemid 28553469)
16. Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, et al. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care 2004; 27: 503-509. (Pubitemid 38174079)
17. Wallerstedt SM, Skrtic S, Eriksson AL, Ohlsson C and Hedner T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 2004; 22: 1277-1281. (Pubitemid 38888072)
18. Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci USA 1998; 95: 12544-12549. (Pubitemid 28483801)
19. Levite M, Cahalon L, Hershkoviz R, Steinman L and Lider O. Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. J Immunol 1998; 160: 993-1000. (Pubitemid 28049345)
20. Straub RH, Mayer M, Kreutz M, Leeb S, Scholmerich J and Falk W. Neurotransmitters of the sympathetic nerve terminal are powerful chemoattractants for monocytes. J Leukoc Biol 2000; 67: 553-558.
21. Dimitrijevic M, Stanojevic S, Vujic V, Beck-Sickinger A and von Horsten S. Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: Counter regulation through Y1 and Y2/5 receptors. Regul Pept 2005; 124: 163-172. (Pubitemid 39488355)
22. Jarvisalo MJ, Lehtimaki T and Raitakari OT. Determinants of arterial nitrate-mediated dilatation in children: Role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness. Circulation 2004; 109: 2885-2889. (Pubitemid 38780303)
23. Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: The cardiovascular risk in young Finns study. Circulation 2004; 110: 2918-2923. (Pubitemid 39473618)
24. Raitakari OT, Juonala M, Ronnemaa T, Keltikangas-Jarvinen L, Rasanen L, Pietikainen M, et al. Cohort profile: The cardiovascular risk in young Finns study. Int J Epidemiol 2008; 37: 1220-1226.
25. Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U, et al. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann Med 2004; 36: 232-240. (Pubitemid 38680200)
26. Lowenberg EC, Meijers JC and Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010; 68: 242-251.
27. Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U,Heinonen OJ, et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 2001; 15: 1242-1244.
28. Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H and Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J Clin Endocrinol Metab 2003; 88: 3278-3283. (Pubitemid 36877505)
29. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000; 85: 2266-2269. (Pubitemid 32269253)
30. Jarvisalo MJ, Jartti L, Karvonen MK, Pesonen U, Koulu M, Marniemi J, et al. Enhanced endothelium-dependent vasodilation in subjects with Proline7 substitution in the signal peptide of neuropeptide Y. Atherosclerosis 2003; 167: 319-326. (Pubitemid 36773531)
31. Kaipio K, Kallio J and Pesonen U. The effect of endogenous preproneuropeptide Y leucine 7 to proline 7 polymorphism on growth and apoptosis in primary cultured HUVECs. Biol Chem 2009; 390: 899-905.
32. Tremoli E, Camera M, Toschi V and Colli S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-283. (Pubitemid 29305462)
33. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF and de Graaf J. Brachial artery diameter is related to cardiovascular risk factors and intima-media thickness. Eur J Clin Invest 2009; 39: 554-560.
34. Kullo IJ, Malik AR, Bielak LF, Sheedy PF, 2nd, Turner ST and Peyser PA. Brachial artery diameter and vasodilator response to nitroglycerine, but not flow-mediated dilatation, are associated with the presence and quantity of coronary artery calcium in asymptomatic adults. Clin Sci (Lond) 2007; 112: 175-182.
35. Henry RM, Ferreira I, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; the Hoorn Study. Atherosclerosis 2004; 174: 49-56. (Pubitemid 38595439)
36. Caligiuri G, Nicoletti A, Poirier B and Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-753. (Pubitemid 34263151)
37. Major AS, Fazio S and Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002; 22: 1892-1898. (Pubitemid 35315778)
38. Bedoui S, Kuhlmann S, Nave H, Drube J, Pabst R and von Horsten S. Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: Mobilization of B-1-like B-lymphocytes and activated monocytes. J Neuroimmunol 2001; 117: 125-132. (Pubitemid 32600075)
39. Kostidou E, Koliakos G and Kaloyianni M. Increased monocyte alphaL, alphaM and beta2 integrin subunits in diabetes mellitus. Clin Biochem 2009; 42: 634-640.
40. Kassirer M, Zeltser D, Prochorov V, Schoenman G, Frimerman A, Keren G, et al. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: Further evidence for smoldering inflammation in patients with atherosclerosis. Am Heart J 1999; 138: 555-559. (Pubitemid 29428780)
41. Kubo N, Boisvert WA, Ballantyne CM and Curtiss LK. Leukocyte CD11b expression is not essential for the development of atherosclerosis in mice. J Lipid Res 2000; 41: 1060-1066. (Pubitemid 30483009)